Open AccessA Treatment-free Interval Allowed by Ponatinib as Fourth-line Therapy
Author(s) -
Anna Bulla,
Uroš Markovic,
Claudia Bellofiore,
Stefania Stella,
Concetta Conticello,
Francesco Di Raimondo,
Fabio Stagno
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10003
Subject(s) - ponatinib , discontinuation , medicine , tyrosine kinase inhibitor , oncology , myeloid leukemia , intensive care medicine , dasatinib , imatinib , cancer
The third-generation tyrosine kinase inhibitor ponatinib has demonstrated high clinical efficacy in the setting of patients with resistant chronic phase chronic myeloid leukemia (CML), also inducing deep molecular responses. However, ponatinib-related cardiovascular toxicities make management challenging, especially of those patients with CML with previous cardiovascular comorbidities.